

REVIEW ARTICLE

Chalcone-xanthine Hybrid: Its Expected Role in Treatment of Non-small Cell Lung Cancer

Omar M. Elrehany^{1*} · Al-Shaimaa F.F. Ahmed² · Maiiada H. Nazmy¹

Received: 16 November 2024 | Accepted: 30 November 2024

¹ Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.

² Department of Pharmacology, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.

Correspondence

Omar M. Elrehany, Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.

E-mail: o_elrehany@yahoo.com

Abstract

Cancer is a complex illness that kills millions of people globally each year. Its origin and growth are highly complicated. The treatment of cancer includes surgery, chemotherapy, and radiation, which can be used separately or in conjunction. However, side effects and multidrug resistance (MDR) are serious obstacles to effective cancer treatment. Chalcone family members have received high interest because of their synthetic and biosynthetic production, besides the broad range of their biological activities. Chalcone targets a wide range of molecular cascades that share in the control of apoptosis and cell cycle growth. Chalcone hybrids especially with xanthine derivatives have approved antineoplastic activity. This review highlights the mechanisms of action of chalcone alone or in hybrids in cancer cells with impact on lung cancer especially non-small cell lung cancer. It also clears the expected mechanisms that regulate apoptosis and cell cycle arrest as an important target in cancer.

Keywords

B-cell lymphoma 2 protein (Bcl-2), Chalcone, Non-small Cell Lung Cancer (NSCLC), Multi-drug Resistance (MDR)

1. Introduction

Lung cancer is an important cause of mortality. Individuals have cancer suffer from lowered life quality due to the bad effects linked with cancer. Chemotherapy is one of the most efficient ways for inhibiting tumor development besides its related side effects such as nausea, vomiting, anemia and thrombocytopenia (Miller et al., 2016).

Through 2018, statistics showed a high number of new cases of lung cancer reach 2.1 million, besides 1.8 million deaths, making it the principal cause of cancer mortality worldwide (Bray et al., 2018). The early detection of lung cancer is becoming more common each year, while death rates are decreasing due to the new detection and diagnosis procedures. However, in less developed nations, Lung cancer often classified as either progressed or locally advanced. As a result, overall in 2019, the 5-year survival rate stays at 19% (Siegel and Miller, 2019). As a result, the development and identification of new candidate molecules implicated in lung cancer therapy is critical.

Lung cancer was shown to be common in high-income countries/regions. This reflects high rate of consumption of tobacco (Chavan et al., 2014; Bray et al., 2018). However, the particular incidence of small cell lung cancer (SCLC) in various countries/regions is not completely clear. SCLC is a high-grade neuroendocrine carcinoma that mostly affects current or former smokers and has a very bad prognosis (Lawrence et al., 2011). SCLC accounts for roughly 15% of lung cancer cases. Patients with SCLC typically present with respiratory symptoms such as cough, dyspnea, or hemoptysis, with imaging showing a centrally located lung mass and sometimes combined with bulky thoracic lymph node (Hou et al., 2012). SCLC accounts for 250,000 new cases annually and at least 200,000 deaths worldwide

(Chavan et al., 2014). SCLC therapy remains identical for subtypes regardless to transcription factor expression profiles that classifies SCLC (Kalemkerian et al., 2018).

The incidence of SCLC globally is high in males (Govindan et al., 2006). SCLC incidence in the United States is reduced in a descending manner through the last three decades reflecting a decreased frequency of cigarette smoking (Breitling et al., 2020). Although the high frequency of smoking among African-American, SCLC is less common than in white Americans (Bade and Cruz, 2020).

Methylxanthines over theophylline shows anticancer properties. Furthermore, Pentoxifylline used in adjuvant therapy to increase the effect of chemotherapy and radiotherapy (Bravo-Cuellar et al., 2013). Anticancer co-therapy with pentoxifylline and doxorubicin showed a synergistic effect and inhibits proliferation of neoplastic cells in a manner higher than each drug alone (Goel and Gude, 2014).

The use of hybrid molecules is an important way for improvement of potency of antineoplastic drugs and minimizes the drug resistance. Naturally occurring chalcones are compounds that have large scale of biological activities like anticancer that exert their effect through many mechanisms (Ahmed et al., 2018).

2. Chalcone

Phytochemicals such as chalcone can affect important mechanisms that contribute to cancer's origin and development. Therefore, scientists integrated folk medicine and knowledge about the use of medicinal plants to synthesize novel, potent, and more effective therapeutic anticancer medicines by application of various molecular processes

(Manzo, 2021). A molecule called chalcone can be found in a variety of natural goods, such as teas, fruits, vegetables, and spices. Chalcone belongs to the family of flavonoids and according to its structural heterogeneity it targets many drug destinations (Zhuang et al., 2017). Chalcone family members have received a lot of attention because of their potential for synthetic and biosynthetic production, as well as the broad range of their biological activities. They include antioxidant, anti-diabetic, anti-cancer, anti-leishmanial, anti-microbial, anti-malarial, anti-inflammatory and cancer chemo preventive properties. More significantly, numerous chalcone compounds have been authorized for clinical use as vascular, mucoprotective, and diuretic agents (Cheng et al., 2020).

2.1. Expected Mechanisms of Action of Chalcone

Chalcone targets many molecular pathways that may contribute to their anti-neoplastic activity that are summarized as follows:

2.1.1. Chalcone and NF- κ B Pathway

The transcription factor, nuclear factor kappa B (NF- κ B), affects inflammation, cancer and innate immunity. Signaling through NF- κ B pathway contributes to progression of cancer by up-regulating survival genes and cytokines predisposing to cancer (e.g., Bcl-2), inhibiting apoptosis, while increasing angiogenesis resulting in an invasive cancer phenotype (Hoesel and Schmid, 2013). NF- κ B inhibitors (IKKs) may trigger an anticancer response or enhance the sensitivity of antitumor drugs. IKKs control NF- κ B activity, which plays a key role in immunological responses and inflammation. Inhibiting NF- κ B activity by IKK inhibition can reduce NF- κ B translocation from cytoplasm to the nucleus, making it a possible therapy method for diseases including inflammation and cancer (Baldwin, 2012). Chalcone inhibits NF- κ B by covalently modifying the I κ B kinase (IKK) proteins. (Lee et al., 2012) and his colleagues discovered that chalcone derivative butein can down regulate NF- κ B gene expression and activity by conjugation with cysteine residue 179 of IKK protein and also inhibits phosphorylation and degradation of I κ B α . Chalcone derivatives suppress expression of inflammatory mediators, including TNF- α , COX-2 and iNOS, by inhibition of the NF- κ B signaling pathway. Finally, chalcone evolved as new mechanisms targeting inflammation and invasion to produce neoplastic chemopreventive treatments (Gan et al., 2018).

2.1.2. Chalcone as Inhibitors of MDR Channels

Chalcone has been investigated for its ability to generate resistance to famous anticancer drugs by modulation of transporters controlling drug efflux, which play an important role in accumulation of drugs in cancer cells. The majority of the investigated chalcone inhibited three members of the ATP-binding cassette transporter family; breast cancer-resistance protein (BCRP, ABCG2), multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein, all of which contribute significantly to multi drug resistance (MDR) in cancer cells. As a result, chalcone has sparked substantial importance as chemotherapeutics to neglect drug resistance and to improve the pharmacokinetics of anticancer medications with delayed absorption (Vasan et al., 2019).

2.1.3. Chalcone Target the p53 Pathway

The tumor suppressor protein p53 controls cell cycle progress and suppresses tumors. p53 is essential for preserving cellular and genomic integrity, as well as limiting the development of cancer cells. p53 is destroyed by a variety of molecules, including MDM2 and Sirtuin-1. Inhibiting the tumor suppressor gene product p53 breakdown is an important anticancer therapeutic strategy (Stein et al., 2019). p53 is negatively regulated by MDM2. The E3 ubiquitin ligase, MDM2, suppresses the activity of p53 by continuous ubiquitinating p53, a mechanism needed for p53 degradation by proteasomes in the nucleus and cytoplasm (Karni-Schmidt et al., 2016). Thus, disrupting p53-MDM2 complex formation is a corner stone in the activation of p53.

(Silva et al., 2016) reported that trans-chalcone (TChal) may inhibit expression of the transcription factor specificity proteins 1 (Sp1), needed for cell differentiation and proliferation, while up-regulating expression of p53 in osteosarcoma cells.

2.1.4. Chalcone as Inhibitors of Angiogenesis

Angiogenesis is a prospective target for cancer therapy because it plays a significant role in cancer development and metastasis. Chalcone has been shown to affect various stages of angiogenesis, including VEGF, bFGF, TGF- β signaling, HIF-1, matrix metalloproteinase activity, migration and proliferation of endothelial cells (Shanmugam et al., 2017).

Ma et al. (2020) and his coworkers discovered that a 3',5'-diprenylated chalcone derivative inhibits Flt-1 (friend leukemia integration-1) and regulates the expression of ICAM-1 (intercellular cell adhesion molecule-1), vascular endothelial growth factor-1 (VEGF-1), MMP-1, TGF- β 2 and p53 genes. These genes are linked to prostate cancer invasion, migration and apoptosis.

2.1.5. Chalcone Target Tubulin Polymerization

Tubulin is a protein that is essential for all eukaryotic cells during mitosis. It is made up of two subunits, α and β , that are related but not identical. The discovery of chalcone as an antimetabolic agent occurred about 3 decades ago. According to research on the structure-activity relationship between colchicine and tubulin, chalcone derivatives resemble colchicine and can bind to tubulin to stop its polymerization. This disrupts the assembly of the mitotic spindle, which interferes with the cytoskeleton's ability to function and mitosis completion (Mirzaei and Emami, 2016).

Many chalcones can bind to β -tubulin and destabilize microtubule polymers, acting as analogs to combretastatin 4A. Ducki et al. (2009) and his coworkers synthesized and produced CA-4 type chalcone and α -phenyl chalcone that demonstrated strong suppression of polymerization of tubulin, arrest cell cycle at the G2/M phase, and potential anti-vascular action.

3. Xanthine-Chalcone Hybrids

The purine base xanthine is found in some plants, urinary calculi and many body fluids and tissues. Degradation of AMP into uric acid includes xanthine intermediate which is produced from hypoxanthine oxidation. Theophylline, theobromine and caffeine are methylated xanthines used with their derivatives as bronchodilators (Hisham et al., 2019).

Xanthine derivatives were tested for their biological effects. They possess diverse biological activities that include anti-inflammatory, CNS stimulant, antimicrobial, adenosine receptor antagonists, antiasthmatic, inhibitors for PDE (phosphodiesterase) and PEPCK (phosphoenol pyruvate carboxykinase) and antitumor activity. Wu et al. (2019) found that theophylline and caffeine promote apoptosis, and enhance doxorubicin induced cytotoxicity

Hybrid molecules have the ability to increase selectivity and activity of chemotherapeutics and beat on drug resistance. As a result, hybridization of anticancer pharmacophores with chalcone is a novel method for developing new anticancer medications. Many chalcone hybrids were synthesized and tested for their antineoplastic activity. Some have considerable in vivo and in vitro activity and this indicates their powerful anticancer medications (Feng et al., 2020).

It was found that apoptosis is induced in many human cancer cell lines through adjuvant therapy of theophylline with gemcitabine or cisplatin. The mechanism of apoptosis induction of theophylline is thought to be

across reduction of intracellular levels of the anti-apoptotic protein Bcl2 (Hisham et al., 2019), targeting p53 or cell cycle arrest as mentioned later.

4. Targeting Bcl-2 Family

The mitochondria-dependent intrinsic pathway is a key apoptotic route. Thus, targeting this pathway is a viable method for inducing apoptosis (Hassan et al., 2014). The Bcl-2 family plays an important role in intrinsic pathways that increase or inhibit mitochondrial membrane permeability, which is required for the release or inhibition of cytochrome-c and other apoptotic proteins (Green and Kroemer, 2004). Because anti-apoptotic proteins decrease apoptosis while increasing cell survival and proliferation, several studies have linked their overexpression to tumor growth and progression (Gautschi et al., 2001).

(Nangia et al., 2018) and his colleagues revealed that the combined treatment of MEK and MCL1 inhibition produces apoptosis and tumor support in KRAS mutant NSCLC. This was synergized by the initial exposure to Bcl-XL inhibitors, which enhances the binding of pro-apoptotic Bcl-2 proteins to MCL-1. Graviola, a plant-derived molecule, has shown anticancer activity. A research discovered that it inhibits Bcl-2 proteins, boosts Bax, and induces apoptosis (Pfeffer and Singh, 2018). The specific mechanism is not yet fully known, although it shows promise efficacy as a cancer therapy.

5. Targeting the Tumor Suppressor Gene P53

Multiple anticancer drugs target p53-mediated pathways because it is a tumor inhibitor and pro-apoptotic protein that causes apoptosis. For decades, p53 has been known to begin DNA repair by increasing the expression of certain target genes by binding to their regulatory areas (Vogelstein et al., 2000). Repairing damaged DNA is the main goal. However, p53 activation will result in cell cycle arrest or death if DNA is significantly damaged (Vermeulen et al., 2003). P53 activity is necessary to stop tumors from growing. As a result, a lot of recently developed anticancer treatments aim to induce cell death by activating or refolding the mutant p53 pathway (Blaydes et al., 2000). This could be achieved by directly targeting p53 or by using small molecules that can restore p53 function. Additionally, focusing on its target gene products, like the pro-apoptotic Bax protein, which can activate the intrinsic apoptotic pathway, inhibit Bcl-2 expression, and induce apoptosis (Beberok et al., 2018).

6. Initiating Cell Cycle Arrest to Induce Apoptosis

One potential target for cancer treatment is the family of cyclin-dependent kinases (CDKs), which regulate and track the stages of the cell cycle. For many years, CDKs were thought to be the main players in the cell cycle, development, differentiation, and proliferation. But recently, interesting targets have been identified, including protein kinases that regulate mitosis and those that act on DNA damage (Fathy et al., 2017). DNA lesions cause cell cycle stop, which enables the cell to fix damaged DNA.

Two essential checkpoints, 1 and 2, are thought to preserve DNA integrity and function as self-cell defenses against cancer by stopping the cell cycle through the activation of serine-threonine protein kinase. The BCR-ABL protein kinase inhibitor "imatinib" from Gleevec; Novartis, which effectively targets tyrosine kinases for the treatment of chronic myelogenous leukemia, was developed as a result of trials for the manufacturing of kinase inhibitors as anticancer medicines. Targeting CDK family members—specifically, CDK-2, 4, and 5—is a useful addition to the list of therapies for inducing apoptosis, according to multiple studies. According to other studies, CDK1 may be involved in prostate cancer, while CDK5 plays a particular function in regulating cell motility and metastasis in this disease (Strock et al., 2006).

7. Conclusion

The anticancer effect of chalcone hybrid on HOP-92 cells was investigated. It reduced proliferation, triggered apoptosis, and stalled the G2/M phase. Furthermore, chalcone hybrid decreased Bcl-2 expression while increasing P53, caspases 3, 8, 9, and the pro-apoptotic production of Bax at the transcriptional level. Furthermore, chalcone treatment suppressed phosphorylation of downstream proteins involved in propagation of cell cycle and apoptosis regulation. These findings emphasize the compound's possible anticancer properties, indicating that it might be used as a novel therapy for the treatment of NSCLC (Elrehany et al., 2024).

8. References

- Ahmed FF, Abdel El-Hafeez AA, Abbas SH, Abdelhamid D, Abdel-Aziz M (2018). New 1, 2, 4-triazole-Chalcone hybrids induce Caspase-3 dependent apoptosis in A549 human lung adenocarcinoma cells. *Eur J Med Chem.*, 151: 705-722. DOI: [10.1016/j.ejmech.2018.03.073](https://doi.org/10.1016/j.ejmech.2018.03.073).
- Bade BC, Cruz CSD (2020). Lung cancer 2020: epidemiology, etiology, and prevention. *Clin Chest Med.*, 41(1): 1-24. DOI: [10.1016/j.ccm.2019.10.001](https://doi.org/10.1016/j.ccm.2019.10.001).
- Baldwin AS (2012). Regulation of cell death and autophagy by IKK and NF- κ B: critical mechanisms in immune function and cancer. *Immunol Rev.*, 246(1): 327-345. DOI: [10.1111/j.1600-065X.2012.01095.x](https://doi.org/10.1111/j.1600-065X.2012.01095.x).
- Beberok A, Wrzeński D, Rzepka Z, Respondek M, Buszman E (2018). Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. *Int J Oncol.*, 52(5): 1727-1737. DOI: [10.3892/ijo.2018.4310](https://doi.org/10.3892/ijo.2018.4310).
- Blaydes JP, Craig AL, Wallace M, Ball H, Traynor NJ, Gibbs NK, Hupp TR (2000). Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. *Oncogene*, 19(34): 3829-3839. DOI: [10.1038/sj.onc.1203773](https://doi.org/10.1038/sj.onc.1203773).
- Bravo-Cuellar, Hernández-Flores AG, Lerma-Díaz JM, Domínguez-Rodríguez JR, Jave-Suárez LF, De Célis-Carrillo R, Aguilar-Lemarroy A, Gómez-Lomeli P, Ortiz-Lazareno PC (2013). Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65. *J Biomed Sci.*, 20(1): 13. DOI: [10.1186/1423-0127-20-13](https://doi.org/10.1186/1423-0127-20-13).
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.*, 68(6): 394-424. DOI: [10.3322/caac.21492](https://doi.org/10.3322/caac.21492).
- Breitling LP, Rinke A, Gress TM (2020). Recent survival trends in high-grade neuroendocrine neoplasms and lung cancer. *Neuroendocrinol.*, 110(3-4): 225-233. DOI: [10.1159/000500883](https://doi.org/10.1159/000500883).
- Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A (2014). International variations in bladder cancer incidence and mortality. *Eur Urol.*, 66(1): 59-73. DOI: [10.1016/j.eururo.2013.10.001](https://doi.org/10.1016/j.eururo.2013.10.001).
- Cheng P, Yang X, Huang L, Wang X, Gong M (2020). Chalcone hybrids and their antimalarial activity. *Arch Pharm.*, 353(4): 1900350. DOI: [10.1002/ardp.201900350](https://doi.org/10.1002/ardp.201900350).
- Ducki S, Mackenzie G, Greedy B, Armitage S, Chabert JFD, Bennett E, Nettles J, Snyder JP, Lawrence NJ (2009). Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. *BMCL*, 17(22): 7711-7722. DOI: [10.1016/j.bmc.2009.09.044](https://doi.org/10.1016/j.bmc.2009.09.044).
- Elrehany OM, Ahmed AFF, Abou-Zied HA, Hayallah AM, Abdel-Aziz M, Nazmy MH (2024). Investigation of anticancer mechanisms of a chalcone/xanthine hybrid in Non-Small Cell Lung Cancer. *BPSAU*. DOI: [10.21608/bfsa.2024.305647.2224](https://doi.org/10.21608/bfsa.2024.305647.2224).
- Fathy M, Awale S, Nikaido T (2017). Phosphorylated Akt protein at Ser473 enables HeLa cells to tolerate nutrient-deprived conditions. *APJCP*. 18(12): 3255. DOI: [10.22034/APJCP.2017.18.12.3255](https://doi.org/10.22034/APJCP.2017.18.12.3255).
- Feng LS, Xu Z, Chang L, Li C, Yan XF, Gao C, Ding C, Zhao F, Shi F, Wu X (2020). "Hybrid molecules with potential in vitro antiplasmodial and in vivo antimalarial activity against drug-resistant *Plasmodium falciparum*. *Med Res Rev.*, 40(3): 931-971. DOI: [10.1002/med.21643](https://doi.org/10.1002/med.21643).

- Gan FF, Zhang R, Ng HL, Karuppasamy M, Seah W, Yeap WH, Ong SM, Hadadi E, Wong SC, Chui WK (2018).** Novel dual-targeting anti-proliferative dihydrotriazine-chalcone derivatives display suppression of cancer cell invasion and inflammation by inhibiting the NF- κ B signaling pathway. *FCT.*, 116: 238-248. DOI: [10.1016/j.fct.2018.04.003](https://doi.org/10.1016/j.fct.2018.04.003).
- Gautschi O, Tschopp S, Olie RA, Leech SH, Simões-Wüst AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA (2001).** Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. *JNCI.*, 93(6): 463-471. DOI: [10.1093/jnci/93.6.463](https://doi.org/10.1093/jnci/93.6.463).
- Goel PN, Gude RP (2014).** Pentoxifylline regulates the cellular adhesion and its allied receptors to extracellular matrix components in breast cancer cells. *Biomed Pharmacother.*, 68(1): 93-99. DOI: [10.1016/j.biopha.2013.09.002](https://doi.org/10.1016/j.biopha.2013.09.002).
- Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J (2016).** Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. *J Clin Oncol.*, 24(28): 4539-4544. DOI: [10.1200/JCO.2005.04.4859](https://doi.org/10.1200/JCO.2005.04.4859).
- Green DR, Kroemer G (2004).** The pathophysiology of mitochondrial cell death. *Sci.*, 305(5684): 626-629. DOI: [10.1126/science.1099320](https://doi.org/10.1126/science.1099320).
- Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. (2014).** Apoptosis and molecular targeting therapy in cancer. *Biomed Res Int.*, 2014. DOI: [10.1155/2014/150845](https://doi.org/10.1155/2014/150845).
- Hisham M, Yousif BG, Osman EEA, Hayallah AM, Abdel-Aziz M (2019).** Synthesis and biological evaluation of novel xanthine derivatives as potential apoptotic antitumor agents. *Eur J Med Chem.*, 176: 117-128. DOI: [10.1016/j.ejmech.2019.05.015](https://doi.org/10.1016/j.ejmech.2019.05.015).
- Hoesel B, Schmid JA (2013).** The complexity of NF- κ B signaling in inflammation and cancer. *Mol Cancer.*, 12(1): 1-15. DOI: [10.1186/1476-4598-12-86](https://doi.org/10.1186/1476-4598-12-86).
- Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest L, Greystoke A, Zhou C, Morris K (2012).** Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. *J Clin Oncol.*, 30(5): 525-532. DOI: [10.1200/JCO.2010.33.3716](https://doi.org/10.1200/JCO.2010.33.3716).
- Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Bumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ (2018).** NCCN guidelines insights: small cell lung cancer, version 2.2018. *JNCCN.*, 16(10): 1171-1182. DOI: [10.6004/jnccn.2018.0079](https://doi.org/10.6004/jnccn.2018.0079).
- Karni-Schmidt O, Lokshin M, Prives C (2016).** The roles of MDM2 and MDMX in cancer. *Annu Rev Pathol: Mechanisms of Disease* 11: 617-644. DOI: [10.1146/annurev-pathol-012414-040349](https://doi.org/10.1146/annurev-pathol-012414-040349).
- Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA (2011).** *Cancer: Principles & Practice of Oncol.*, Lippincott Williams & Wilkins.
- Lee YH, Jeon SH, Kim SH, Kim C, Lee SJ, Koh D, Lim Y, Ha K, Shin SY (2012).** A new synthetic chalcone derivative, 2-hydroxy-3', 5', 5'-trimethoxychalcone (DK-139), suppresses the Toll-like receptor 4-mediated inflammatory response through inhibition of the Akt/NF- κ B pathway in BV2 microglial cells. *Exp Mol Med.*, 44(6): 369-377. DOI: [10.3858/emm.2012.44.6.042](https://doi.org/10.3858/emm.2012.44.6.042).
- Ma Y, Xu B, Yu J, Huang L, Zeng X, Shen X, Ren C, Ben-David Y, Luo H (2020).** Fli-1 activation through targeted promoter activity regulation using a novel 3', 5'-diprenylated chalcone inhibits growth and metastasis of prostate cancer cells. *Int J Mol Sci.*, 21(6): 2216. DOI: [10.3390/ijms21062216](https://doi.org/10.3390/ijms21062216).
- Manzo E (2021).** Synthesis of marine natural products and molecules inspired by marine substances, MDPI. 19: 208. DOI: [10.3390/md19040208](https://doi.org/10.3390/md19040208).
- Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016).** Cancer treatment and survivorship statistics, 2016. *CA: Cancer J Clin.*, 66(4): 271-289. DOI: [10.3322/caac.21349](https://doi.org/10.3322/caac.21349).
- Mirzaei H, Emami S (2016).** Recent advances of cytotoxic chalconoids targeting tubulin polymerization: Synthesis and biological activity. *Eur J Med Chem.*, 121: 610-639. DOI: [10.1016/j.ejmech.2016.05.067](https://doi.org/10.1016/j.ejmech.2016.05.067).
- Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C (2018).** Exploiting MCL1 dependency with combination MEK+ MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-mutant non-small cell lung cancer. *Cancer Discov.*, 8(12): 1598-1613. DOI: [10.1158/2159-8290.CD-18-0277](https://doi.org/10.1158/2159-8290.CD-18-0277).
- Pfeffer CM, Singh AT (2018).** Apoptosis: a target for anticancer therapy. *Int J Mol Sci.*, 19(2): 448. DOI: [10.3390/ijms19020448](https://doi.org/10.3390/ijms19020448).
- Shanmugam MK, Warriar S, Kumar AP, Sethi G, Arfuso F (2017).** Potential role of natural compounds as anti-angiogenic agents in cancer. *Curr Vasc Pharmacol.*, 15(6): 503-519. DOI: [10.2174/1570161115666170713094319](https://doi.org/10.2174/1570161115666170713094319).
- Siegel RL, Miller KD (2019).** Jemal, A30620402: Cancer statistics, 2019. vol. 69, issue 1. *CA Cancer J Clin*: 7-34. DOI: [10.3322/caac.21551](https://doi.org/10.3322/caac.21551).
- Silva G, Marins M, Fachin AL, Lee SH, Baek SJ (2016).** Anti-cancer activity of trans-chalcone in osteosarcoma: involvement of Sp1 and p53. *Mol Carcinog.*, 55(10): 1438-1448. DOI: [10.1002/mc.22386](https://doi.org/10.1002/mc.22386).
- Stein Y, Rotter V, Aloni-Grinstein R (2019).** Gain-of-function mutant p53: all the roads lead to tumorigenesis. *Int J Mol Sci.*, 20(24): 6197. DOI: [10.3390/ijms20246197](https://doi.org/10.3390/ijms20246197).
- Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD (2006).** Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. *Cancer Res.*, 66(15): 7509-7515. DOI: [10.1158/0008-5472.CAN-05-3048](https://doi.org/10.1158/0008-5472.CAN-05-3048).
- Vasan N, Baselga J, Hyman DM (2019).** A view on drug resistance in cancer. *Nature.*, 575(7782): 299-309. DOI: [10.1038/s41586-019-1730-1](https://doi.org/10.1038/s41586-019-1730-1).
- Vermeulen K, Berneman ZN, Van Bockstaele DR (2003).** Cell cycle and apoptosis. *Cell Prolif.*, 36(3): 165-175. DOI: [10.1046/j.1365-2184.2003.00267.x](https://doi.org/10.1046/j.1365-2184.2003.00267.x).
- Vogelstein B, Lane D, Levine AJ (2000).** Surfing the p53 network. *Nature.*, 408(6810): 307-310. DOI: [10.1038/35042675](https://doi.org/10.1038/35042675).
- Wu J, Dai J, Zhang Y, Wang J, Huang L, Ding H, Li T, Zhang Y, Mao J, Yu S (2019).** Synthesis of novel xanthone analogues and their growth inhibitory activity against human lung cancer A549 cells. *Drug Des Devel Ther.*, 4239-4246. DOI: [10.2147/DDDT.S217827](https://doi.org/10.2147/DDDT.S217827).
- Zhuang C, Zhang W, Sheng C, Zhang W, Xing C, Miao Z (2017).** Chalcone: a privileged structure in medicinal chemistry. *Chem Rev.*, 117(12): 7762-7810. DOI: [10.1021/acs.chemrev.7b00020](https://doi.org/10.1021/acs.chemrev.7b00020).

How to cite this article:

Elrehany OM, Ahmed AFF, Nazmy MH. Chalcone-xanthine Hybrid: Its Expected Role in Treatment of Non-small Cell Lung Cancer. *J Vet Med Res.*, 2024; 32(2): 52–55. <https://doi.org/10.21608/jvmr.2024.336602.1109>.